Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

18.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.7K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.5K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Comment: Highlighting the Opportunity for Advanced Neuroimaging in the Presurgical Evaluation of Adults With Medically Refractory Epilepsy.

AJR. American journal of roentgenology·2022
Same author

Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]).

European journal of cancer (Oxford, England : 1990)·2021
Same author

The flip-flop fungus sign: an FDG PET/CT sign of benignity.

American journal of nuclear medicine and molecular imaging·2017
Same author

Multimodality Imaging of Neurodegenerative Processes: Part 2, Atypical Dementias.

AJR. American journal of roentgenology·2016
Same author

Multimodality Imaging of Neurodegenerative Processes: Part 1, The Basics and Common Dementias.

AJR. American journal of roentgenology·2016
Same author

Spectrum of Benign Articular and Periarticular Findings at FDG PET/CT.

Radiographics : a review publication of the Radiological Society of North America, Inc·2016

Related Experiment Video

Updated: Apr 15, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Multiple myeloma.

Patrick J Peller1

  • 1Eka Medical Center - Jakarta, Central Business District Lot IX, BSD City, Tangerang 15321, Indonesia.

PET Clinics
|April 2, 2015
PubMed
Summary

This review covers multiple myeloma and related plasma cell disorders. Fluorodeoxyglucose PET/CT shows growing utility in evaluating and managing these conditions.

Area of Science:

  • Hematology
  • Oncology
  • Radiology

Background:

  • Multiple myeloma is a malignant plasma cell disorder.
  • Precursor states and related plasma cell dyscrasias share diagnostic and management considerations.
  • Accurate staging and monitoring are crucial for effective patient management.

Purpose of the Study:

  • To review current understanding of multiple myeloma and precursor states.
  • To discuss the role of fluorodeoxyglucose PET/computed tomography (PET/CT) in evaluating plasma cell disorders.
  • To highlight the potential of PET/CT to improve patient management.

Main Methods:

  • Literature review of multiple myeloma, precursor states, and plasma cell disorders.
  • Analysis of clinical and research data on fluorodeoxyglucose PET/CT utility.
Keywords:
FluorodeoxyglucoseMonoclonal gammopathyMultiple myelomaPETPET/CTPlasmacytoma

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Experiment Videos

Last Updated: Apr 15, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K
  • Discussion of imaging findings and their impact on patient care.

    • Main Results:

    • Growing evidence supports the utility of PET/CT in diagnosing and monitoring multiple myeloma.
    • PET/CT can provide valuable information beyond conventional imaging for plasma cell dyscrasias.
    • The integration of PET/CT may enhance treatment response assessment and prognostication.

    Conclusions:

    • Fluorodeoxyglucose PET/CT is an increasingly important tool in the management of multiple myeloma and related plasma cell disorders.
    • Further research will continue to define the optimal applications of PET/CT in this field.
    • PET/CT has the potential to personalize treatment strategies and improve outcomes for patients.